CIK: 0001766721 · Show all filings
Period: Q3 2020 (← Previous) (Next →)
Filing Date: Nov 12, 2020
Total Value ($000): $313,036 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc (BBIO) | 3,989,412 | $149,683 | 47.8% | $27.40 | +14.8% | COM | 10806X102 |
| — | Eidos Therapeutics, Inc. (EIDIX) | 1,123,630 | $56,777 | 18.1% | $13.76 | — | COM | 28249H104 |
| HRMY | HARMONY BIOSCIENCES HLDGS IN (HRMY) | 842,815 | $28,571 | 9.1% | $36.46 | 0.0% | COM | 413197104 |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | 1,025,000 | $15,129 | 4.8% | $10.24 | +48.9% | COM | 87164F105 |
| — | AVROBIO, Inc. (AVRO) | 1,009,779 | $13,147 | 4.2% | $16.72 | — | COM | 05455M100 |
| — | Aeglea Biotherapeutics Inc (AGLE) | 1,691,151 | $11,990 | 3.8% | $8.00 | — | COM | 00773J103 |
| — | POSEIDA THERAPEUTICS INC (PSTX) | 1,043,267 | $9,254 | 3.0% | $8.87 | — | COM | 73730P108 |
| — | Verona Pharma plc (VRNA) | 1,332,485 | $8,315 | 2.7% | $7.38 | — | COM | 925050106 |
| — | Atreca Inc (BCEL) | 387,653 | $5,416 | 1.7% | $18.84 | — | CL A COM | 04965G109 |
| — | Zosano Pharma Corporation (ZSAN) | 2,718,226 | $4,404 | 1.4% | $2.15 | — | COM | 98979H202 |
| — | ObsEva SA (OBSV) | 1,386,338 | $3,438 | 1.1% | $12.66 | — | COM | H5861P103 |
| — | Marker Therapeutics, Inc. (MRKR) | 2,000,000 | $3,000 | 1.0% | $5.55 | — | COM | 57055L107 |
| ACRS | Aclaris Therapeutics Inc (ACRS) | 634,455 | $1,631 | 0.5% | $10.31 | -78.3% | COM | 00461U105 |
| — | Sunesis Pharmaceuticals, Inc. (SNSS) | 1,010,000 | $1,263 | 0.4% | $0.89 | — | COM | 867328700 |
| — | Nabriva Therapeutics plc (NBRV) | 1,910,287 | $1,018 | 0.3% | $1.49 | — | SHS | G63637105 |